Amyloidosis Trials in London, United Kingdom
Conditions / Amyloidosis / London, United Kingdom
Clinical trials for Amyloidosis investigate a range of treatment strategies and patient populations.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. | RECRUITING | PHASE1/PHASE2 |
| NCT03860935 | Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy | COMPLETED | PHASE3 |
| NCT05250973 | A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT01215747 | Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis | COMPLETED | PHASE3 |
| NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING | PHASE3 |
| NCT03774784 | A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease | TERMINATED | — |
| NCT02175004 | Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) | COMPLETED | PHASE3 |
| NCT02510261 | The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) | COMPLETED | PHASE3 |
| NCT03201965 | A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis | COMPLETED | PHASE3 |
| NCT01737398 | Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy | COMPLETED | PHASE2/PHASE3 |